Mexiletine

證據等級: L5

預測適應症: 10 個

Mexiletine: From Ventricular Arrhythmia to Hypertrichosis

One-Sentence Summary

Mexiletine is a Class Ib sodium-channel-blocking antiarrhythmic, historically used for ventricular arrhythmias and (off-label) myotonia/neuropathic pain. The TxGNN model predicts a possible signal for Hypertrichosis (disease), but this is currently supported by 0 clinical trials and 0 publications — a pure model-derived score with no corroborating evidence.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack’s regulatory data (drug not marketed, no TFDA license record). Literature captured elsewhere in this pack confirms mexiletine’s established use as a Class Ib antiarrhythmic for ventricular arrhythmias, and off-label for myotonia/neuropathic pain
Predicted New Indication	Hypertrichosis (disease)
TxGNN Prediction Score	99.78%
Evidence Level	L5
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for mexiletine is not available in this evidence pack (flagged as a High-severity data gap). Based on information present in the supporting literature for other candidates in this pack, mexiletine is a Class Ib sodium-channel blocker in the same pharmacological family as lidocaine, historically used for ventricular arrhythmias and, off-label, for myotonia and neuropathic pain.

For the top-ranked candidate specifically — Hypertrichosis — the model’s own rationale states there is no known mechanistic relationship: “無已知機轉關聯，無臨床試驗與文獻支持，純為 TxGNN 模型預測分數” (no known mechanistic link, no clinical trial or literature support, purely a TxGNN model prediction score). Sodium-channel blockade has no established biological connection to hair follicle growth regulation, and no publication in this pack links mexiletine to hypertrichosis. This candidate should be treated as an unvalidated graph-embedding signal rather than a mechanistically grounded hypothesis.

Notably, other candidates in the same prediction set (not the subject of this report but visible in the underlying data) — headache disorder (L3) and migraine disorder (L4) — do have drug-specific literature (case series and cohort studies on mexiletine for headache/trigeminal autonomic cephalalgias), consistent with its known sodium-channel mechanism. Hypertrichosis has no such support.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

US Market Information

No marketing authorization (NDA) records are available — mexiletine is currently not marketed (未上市) in this jurisdiction, with 0 total licenses on file.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction (Hypertrichosis) is Evidence Level L5 — a model score with zero supporting clinical trials or literature, and the model’s own rationale identifies no plausible mechanistic link between sodium-channel blockade and hair growth. There is no basis to advance this specific candidate.

To proceed, the following is needed:

TFDA warning/contraindication data for mexiletine (currently a Blocking data gap — required before any S1 safety screening)
Verified mechanism of action (MOA) data from DrugBank or equivalent source (currently a High-severity data gap)
Preclinical or mechanistic studies specifically linking sodium-channel blockade to hair follicle/hypertrichosis pathways, if this candidate is to be pursued further
Consider evaluating alternative candidates from the same TxGNN run with stronger drug-specific literature support — headache disorder (L3, Research Question) and migraine disorder (L4, Research Question) both have published case series/cohort data on mexiletine — as separate, higher-priority repurposing candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.